What Is Orforglipron? Eli Lilly's GLP-1 Pill, Explained (2026)

2026 is the year GLP-1 went oral. First came the Wegovy semaglutide pill. Next up is a different kind of pill from Eli Lilly: orforglipron. Here's what makes it notable.

What it is

Orforglipron is a once-daily oral GLP-1 receptor agonist from Eli Lilly (the maker of Zepbound and Mounjaro). Unlike the Wegovy pill — which is semaglutide in tablet form — orforglipron is a small-molecule drug. FDA approval for weight loss and type 2 diabetes is anticipated in 2026.

The big advantage: no empty-stomach rule (so far)

The Wegovy pill must be taken on an empty stomach, with a wait before food, coffee, or other meds — a real adherence hurdle. Orforglipron, as a small molecule, is being developed without those strict food-timing restrictions. If that holds at launch, it's a meaningful convenience win for daily pill-takers.

How effective is it?

In trials it produced clinically meaningful weight loss in the GLP-1 range. It isn't expected to top the strongest injectables (tirzepatide-class drugs have shown ~18–21% average loss), but for an easy daily pill, the numbers are compelling. Individual results always vary.

Why it matters for prices

More approved GLP-1s = more competition = continued downward pressure on prices. With a $150 oral semaglutide already on the market and direct-to-consumer injections near $350/month, a second oral option could push costs down further through 2026. (See our 2026 price guide.)

Pill vs. pill vs. injection — quick frame

Bottom line

If a daily pill without food-timing rules appeals to you, orforglipron is the 2026 launch to watch. As always, which GLP-1 fits depends on your medical history, insurance, and tolerance — decide with a provider.

Compare GLP-1 clinics → · Wegovy pill explained →

General information, not medical advice. Approval timing and labeling can change; confirm current status with a licensed clinician.